knowledge -WSS

knowledge

author：hotspot 2025-09-27 16:35:19 - browse：9

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Welsh Carson private equity firm escapes from FTC antitrust case

WSS

ALS advocates say criticism of new drugs misses bigger picture

As billionaires fund anti

Why Novartis is changing the name of its research labs

Trump surgeon general acknowledges mistakes during Covid

Chemotherapy before breast cancer surgery might fuel metastasis

PBM executives asked to testify by House panel

entertainment

knowledge

focus

Drug repurposing or repositioning? The language matters

Empower primary care with adequate payments and technology

Trump demands the U.S. pay no more for drugs than other countries … again

Warren pushes Witty on UnitedHealth's control over physicians

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Deliver public health messages at the right time

Dobbs anniversary: the lost opportunity of abortion as health care

Ethical issues complicate the benefits of medical crowdfunding

Malaria cases in Florida and Texas: Here’s what you need to know

AI for drug discovery: Experts on separating hype from reality

hotspot

Humana sues Biden admin over Medicare Advantage audit rule

Deliver public health messages at the right time

Black vets could get higher VA benefits if race not used in lung test

Empower primary care with adequate payments and technology

How generative AI is inspiring dreams of a health data revolution

Brain technologies pose threats that are all too real, experts warn

Wikipedia

hotspot

knowledge

knowledge